Intellia Therapeutics Inc (LTS:0JBU)
$ 15.2288 0.0388 (0.26%) Market Cap: 1.57 Bil Enterprise Value: 982.59 Mil PE Ratio: 0 PB Ratio: 1.53 GF Score: 55/100

Intellia Therapeutics Inc 2022 Bradykinin Symposium Transcript

Sep 16, 2022 / 12:00PM GMT
Release Date Price: $64.47 (-5.56%)
Operator

Good morning, and welcome to Intellia Therapeutics' investor event to discuss interim clinical updates across the company's in vivo pipeline. My name is Andrew, and I will be your conference operator today. Please be advised that this call is being recorded at the company's request. (Operator Instructions)

Following the formal remarks, we will open the call up for your questions. I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.

Ian Karp
Intellia Therapeutics, Inc. - SVP of IR & Corporate Communications

Thank you, operator, and good morning, everyone. Welcome to Intellia's investor webcast to discuss recent advances for our ongoing first-in-human studies of NTLA-2001 and NTLA-2002. Earlier today, we issued two press releases, detailing interim data from these clinical trials. The releases, along with an accompanying presentation for today's call can be found on the Investors & Media section of Intellia's website at intelliatx.com. As a reminder

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot